

# CITATION REPORT

List of articles citing

## Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis

DOI: [10.1056/nejmoa1811737](https://doi.org/10.1056/nejmoa1811737)

New England Journal of Medicine, 2018, 379, 1722-1731.

**Source:** <https://exaly.com/paper-pdf/70863744/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
173	Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis. <b>2018</b> , 10, 5974-5978		1
172	ERS International Congress 2018: highlights from best-abstract awardees. <b>2018</b> , 14, e137-e142		
171	Defining a pathological role for the vasculature in the development of fibrosis and pulmonary hypertension in interstitial lung disease. <b>2019</b> , 317, L431-L433		5
170	Chemokine signaling axis between endothelial and myeloid cells regulates development of pulmonary hypertension associated with pulmonary fibrosis and hypoxia. <b>2019</b> , 317, L434-L444		4
169	Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE). <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 1505-1512	10.2	30
168	Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. Echoes of the Past, Lessons for the Future. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 1459-1461	10.2	1
167	Management of Idiopathic Pulmonary Fibrosis. <b>2019</b> , 53, 1238-1248		12
166	Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study. <b>2019</b> , 15, 144-146		0
165	Real-World Comprehensive Disease Management of Patients With Idiopathic Pulmonary Fibrosis. <b>2019</b> , 15, 4-15		1
164	Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF). <b>2019</b> , 11, S1740-S1754		48
163	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. <b>2019</b> , 7, 771-779		34
162	Hypoxic Pulmonary Vasoconstriction and the Diffusing Capacity in Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis. <b>2019</b> , 8, e013310		4
161	Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. <b>2019</b> , 20, 205		74
160	Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design. <i>Advances in Therapy</i> , <b>2019</b> , 36, 3059-3070	4.1	1
159	Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update. <b>2019</b> , 13, 1139-1146		11
158	Diagnosing complications and co-morbidities of fibrotic interstitial lung disease. <b>2019</b> , 13, 645-658		7
157	A comprehensive and practical approach to the management of idiopathic pulmonary fibrosis. <b>2019</b> , 13, 601-614		3

156	Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2). <b>2019</b> , 6, e000422		50
155	Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Letter]. <b>2019</b> , 13, 1177-1178		1
154	Contemporary Concise Review 2018: Interstitial lung disease. <b>2019</b> , 24, 809-816		3
153	The Effects of Epigallocatechin Gallate (EGCG) on Pulmonary Fibroblasts of Idiopathic Pulmonary Fibrosis (IPF)-A Next-Generation Sequencing and Bioinformatic Approach. <b>2019</b> , 20,		17
152	Adjunctive therapies in idiopathic pulmonary fibrosis-where do we stand?. <b>2019</b> , 11, 357-360		
151	Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 133-139	10.2	3
150	Update in Pulmonary Fibrosis 2018. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 292-300	10.2	6
149	The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. <b>2019</b> , 20, 59		46
148	Current and Future Idiopathic Pulmonary Fibrosis Therapy. <b>2019</b> , 357, 370-373		8
147	Treatment of severe idiopathic pulmonary fibrosis-is sildenafil the next (in)stage?. <b>2019</b> , 11, 339-340		1
146	Novel drug targets in idiopathic pulmonary fibrosis. <i>Expert Opinion on Orphan Drugs</i> , <b>2019</b> , 7, 125-146	1.1	1
145	The Future of Pharmacological Treatment in Idiopathic Pulmonary Fibrosis. <b>2019</b> , 55, 642-647		1
144	Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue. <i>European Respiratory Review</i> , <b>2019</b> , 28,	9.8	37
143	Drugs that act on the respiratory tract. <b>2019</b> , 41, 171-182		1
142	Pulmonary hypertension and chronic lung disease: where are we headed?. <i>European Respiratory Review</i> , <b>2019</b> , 28,	9.8	11
141	The future of pharmacological treatment in idiopathic pulmonary fibrosis. <b>2019</b> , 55, 642-647		0
140	Neue Entwicklungen in der Welt der interstitiellen Lungenerkrankungen. <b>2019</b> , 11, 22-28		
139	Pulmonary hypertension due to interstitial lung disease. <b>2019</b> , 25, 459-467		12

138	Clinical course and management of idiopathic pulmonary fibrosis. <b>2019</b> , 14, 35		6
137	Efficacy data in treatment extension studies of idiopathic pulmonary fibrosis: interpret with caution. <b>2019</b> , 7, 7-8		2
136	Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management. <i>Advances in Therapy</i> , <b>2019</b> , 36, 298-317	4.1	12
135	Existing and emerging treatments for idiopathic pulmonary fibrosis. <b>2019</b> , 13, 229-239		6
134	Comorbidities and survival in patients with chronic hypersensitivity pneumonitis. <b>2020</b> , 21, 12		12
133	Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme. <b>2020</b> , 21, 7		8
132	Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease. <b>2020</b> , 99, 73-82		30
131	Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease. <b>2020</b> , 30, 225-231		19
130	Older Idiopathic Pulmonary Fibrosis Male Patients Are at a Higher Risk of Nintedanib Dose Reduction. <b>2020</b> , 99, 646-648		2
129	ERS International Congress, Madrid, 2019: highlights from the Pulmonary Vascular Diseases Assembly. <i>ERJ Open Research</i> , <b>2020</b> , 6,	3.5	1
128	Vascular dysfunction in aged mice contributes to persistent lung fibrosis. <b>2020</b> , 19, e13196		9
127	The adoption of nintedanib in systemic sclerosis: the SENSICIS study. <b>2020</b> , 16, 200005		2
126	Pan-transcriptome-based candidate therapeutic discovery for idiopathic pulmonary fibrosis. <b>2020</b> , 14, 1753466620971143		4
125	The Potential Effects of Curcumin on Pulmonary Fibroblasts of Idiopathic Pulmonary Fibrosis (IPF)-Approaching with Next-Generation Sequencing and Bioinformatics. <b>2020</b> , 25,		1
124	Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data. <i>Advances in Therapy</i> , <b>2020</b> , 37, 4209-4219	4.1	8
123	Clinical trials in group 3 pulmonary hypertension. <b>2020</b> , 26, 391-396		3
122	Optimizing care for patients with interstitial lung disease during the COVID-19 pandemic. <b>2020</b> , 4, 226-228		1
121	Management of idiopathic pulmonary fibrosis: A survey of Canadian respirologists. <b>2020</b> , 4, 165-173		1

120	Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis. <b>2020</b> , 10, 15620		8
119	Radiation-induced lung toxicity - cellular and molecular mechanisms of pathogenesis, management, and literature review. <b>2020</b> , 15, 214		29
118	The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease: Dilemmas in Diagnosis and the Conundrum of Treatment. <b>2020</b> , 158, 1651-1664		15
117	Update in Interstitial Lung Disease 2019. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 202, 500-507	10.2	3
116	The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease. <b>2020</b> , 14, 1001-1008		1
115	Subtle signs - red flags. <i>European Respiratory Journal</i> , <b>2020</b> , 55,	13.6	1
114	The importance of interventional timing in the bleomycin model of pulmonary fibrosis. <i>European Respiratory Journal</i> , <b>2020</b> , 55,	13.6	27
113	Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment. <b>2020</b> , 21,		8
112	Impact of Depression on Patients With Idiopathic Pulmonary Fibrosis. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 29	4.9	7
111	Patient gender bias on the diagnosis of idiopathic pulmonary fibrosis. <i>Thorax</i> , <b>2020</b> , 75, 407-412	7.3	11
110	Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. <b>2020</b> , 20, 3		29
109	Update in Pulmonary Vascular Diseases and Right Ventricular Dysfunction 2019. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 202, 22-28	10.2	3
108	Vascular permeability in the fibrotic lung. <i>European Respiratory Journal</i> , <b>2020</b> , 56,	13.6	15
107	Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 191-204	4	8
106	Quantification of pulmonary perfusion in idiopathic pulmonary fibrosis with first pass dynamic contrast-enhanced perfusion MRI. <i>Thorax</i> , <b>2021</b> , 76, 144-151	7.3	2
105	Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. <b>2021</b> , 9, 85-95		33
104	MiR-200a inversely correlates with Hedgehog and TGF- $\beta$ canonical/non-canonical trajectories to orchestrate the anti-fibrotic effect of Tadalafil in a bleomycin-induced pulmonary fibrosis model. <b>2021</b> , 29, 167-182		3
103	The Challenge to Decide between Pulmonary Hypertension Due to Chronic Lung Disease and PAH with Chronic Lung Disease. <b>2021</b> , 11,		3

102	Group 3 Pulmonary Hypertension: A Review of Diagnostics and Clinical Trials. <b>2021</b> , 42, 59-70		3
101	Nintedanib: A Review in Fibrotic Interstitial Lung Diseases. <b>2021</b> , 81, 575-586		12
100	Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions. <b>2021</b> , 5, 31-40		
99	Cardiovascular safety of the tyrosine kinase inhibitor nintedanib. <b>2021</b> , 87, 3690-3698		1
98	New Insights into Pathomechanisms and Treatment Possibilities for Lung Silicosis. <b>2021</b> , 22,		11
97	Current and future treatment for idiopathic pulmonary fibrosis. <i>Journal of the Korean Medical Association</i> , <b>2021</b> , 64, 256-263		0.5
96	Update pulmonale Hypertonie mit Fokus auf Lungenkrankheiten. <b>2021</b> , 18, 195-206		
95	Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management. <b>2021</b> , 22, 109		11
94	Inhaled Treprostinil in Group 3 Pulmonary Hypertension. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 1869		59.2
93	An updated safety review of the drug treatments for idiopathic pulmonary fibrosis. <b>2021</b> , 20, 1035-1048		2
92	Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?. <i>European Respiratory Review</i> , <b>2021</b> , 30,	9.8	2
91	Treatment of Idiopathic Pulmonary Fibrosis. <b>2021</b> , 13, e15360		1
90	The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia. <b>2021</b> , 30, 2615-2632		1
89	Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials. <b>2021</b> , 26, 93-101		2
88	Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment. <b>2021</b> , 27, 396-404		4
87	Exploring the Mechanism Whereby Sinensetin Delays the Progression of Pulmonary Fibrosis Based on Network Pharmacology and Pulmonary Fibrosis Models. <b>2021</b> , 12, 693061		1
86	Inhaled trepostinil for severe fibrotic interstitial lung disease: grounds for cautious optimism?. <b>2021</b> , 9, 1209-1211		0
85	Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study. <b>2021</b> , 40, 494-503		5

84	The Potential Role of Sildenafil in Cancer Management through EPR Augmentation. <b>2021</b> , 11,		5
83	Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. <b>2021</b> , 9, 1266-1274		11
82	Die idiopathische pulmonale Fibrose jenseits der Lunge: Krankheitsmechanismen verstehen, um Diagnose und Therapie zu verbessern. 1-12		
81	Emerging drug delivery strategies for idiopathic pulmonary fibrosis treatment. <b>2021</b> , 164, 1-12		6
80	Dopamine receptor agonists ameliorate bleomycin-induced pulmonary fibrosis by repressing fibroblast differentiation and proliferation. <b>2021</b> , 139, 111500		1
79	Characteristics and evaluation of acute exacerbations in chronic interstitial lung diseases. <b>2021</b> , 183, 106400		1
78	Lung transplantation for interstitial lung disease. <i>European Respiratory Review</i> , <b>2021</b> , 30,	9.8	4
77	Combination therapy of tanshinone IIA and puerarin for pulmonary fibrosis via targeting IL6-JAK2-STAT3/STAT1 signaling pathways. <b>2021</b> , 35, 5883-5898		2
76	Assessing pulmonary hypertension severity in lung disease is a key step to improving outcomes: embrace resistance and don't be pressurised to go with the flow. <i>European Respiratory Journal</i> , <b>2021</b> , 58,	13.6	1
75	Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis. <b>2021</b> , 11, 17824		3
74	Pulmonary hypertension in fibrosing idiopathic interstitial pneumonia: Uncertainties, challenges and opportunities. <b>2021</b> , 40, 872-881		0
73	An IPF-like disease course in disorders other than IPF: how can this be anticipated, recognized, and managed?. <i>Expert Review of Clinical Immunology</i> , <b>2021</b> , 17, 1091-1101	5.1	1
72	The Aggregate Index of Systemic Inflammation (AISI): A Novel Prognostic Biomarker in Idiopathic Pulmonary Fibrosis. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	6
71	Development of Anti-fibrotic Therapy in Strictureing Crohn's Disease: Lessons from Randomized Trials in Other Fibrotic Diseases. <i>Physiological Reviews</i> , <b>2021</b> ,	47.9	2
70	Treatment of fibrotic interstitial lung disease: current approaches and future directions. <i>Lancet, The</i> , <b>2021</b> , 398, 1450-1460	40	7
69	Tetraethylthiuram disulphide alleviates pulmonary fibrosis through modulating transforming growth factor- $\beta$ signalling. <i>Pharmacological Research</i> , <b>2021</b> , 174, 105923	10.2	0
68	A Comprehensive Guide to Lung Transplantation for the Recipient With Pulmonary Fibrosis. <b>2022</b> , 661-675		
67	Group 3 PH: Clinical Features and Treatment. <b>2022</b> , 678-690		

66	Comprehensive Care of Interstitial Lung Disease. <b>2022</b> , 64-78		
65	Idiopathic Pulmonary Fibrosis-Treatment and Management. <b>2022</b> , 218-233		
64	Common Co-Morbidities in Fibrosing Interstitial Lung Disease. <b>2022</b> , 79-87		
63	Palliative Care in Interstitial Lung Disease. <i>Respiratory Medicine</i> , <b>2021</b> , 189-207	0.2	
62	Phase three clinical trials in idiopathic pulmonary fibrosis. <i>Expert Opinion on Orphan Drugs</i> , <b>2021</b> , 9, 1-11	1.1	0
61	Evolution and treatment of idiopathic pulmonary fibrosis. <i>Presse Medicale</i> , <b>2020</b> , 49, 104025	2.2	6
60	The therapy of idiopathic pulmonary fibrosis: what is next?. <i>European Respiratory Review</i> , <b>2019</b> , 28,	9.8	68
59	Carbon monoxide in intensive care medicine-time to start the therapeutic application?!. <i>Intensive Care Medicine Experimental</i> , <b>2020</b> , 8, 2	3.7	20
58	A retrospective study of the tolerability of nintedanib for severe idiopathic pulmonary fibrosis in the real world. <i>Annals of Translational Medicine</i> , <b>2019</b> , 7, 262	3.2	12
57	The Clinical Efficacy of Pulmonary Hypertension-Specific Agents in Idiopathic Pulmonary Fibrosis: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. <i>Journal of Korean Medical Science</i> , <b>2020</b> , 35, e48	4.7	4
56	Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology. <i>Jornal Brasileiro De Pneumologia</i> , <b>2020</b> , 46, e20190423	1.1	2
55	Pharmacological treatment of pulmonary fibrosis. <i>Journal of the Korean Medical Association</i> , <b>2020</b> , 63, 47	0.5	4
54	Management of PH-ILD: Past, Present, and Future. <i>Advances in Pulmonary Hypertension</i> , <b>2021</b> , 20, 119-122	2.5	0
53	Health Related Quality of Life in Interstitial Lung Disease: Can We Use the Same Concepts Around the World?. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 745908	4.9	
52	Management of patients with fibrosing interstitial lung diseases. <i>American Journal of Health-System Pharmacy</i> , <b>2021</b> ,	2.2	0
51	Pan-transcriptome-based Candidate Therapeutic Discovery for Idiopathic Pulmonary Fibrosis.		
50	The cardiovascular system in idiopathic pulmonary fibrosis. <b>2020</b> , 198-211		
49	Inhibition of fibrosis with multi-agent therapy in pulmonary fibrosis: Results of a drug library screening.		



48	Idiopathic Interstitial Pneumonias: A Review of the Past and Emerging Therapies. <i>Journal of Pharmacy Practice</i> , <b>2021</b> , 8971900211053286	1.3	
47	Pharmacological treatment of idiopathic pulmonary fibrosis: time to step out of the comfort zone?. <i>Jornal Brasileiro De Pneumologia</i> , <b>2020</b> , 46, e20200193	1.1	
46	The methyl-CpG-binding domain 2 facilitates pulmonary fibrosis by orchestrating fibroblast to myofibroblast differentiation.. <i>European Respiratory Journal</i> , <b>2022</b> ,	13.6	1
45	Gender and racial equity in clinical research for idiopathic pulmonary fibrosis: a systematic review and meta-analysis.. <i>European Respiratory Journal</i> , <b>2022</b> ,	13.6	1
44	Idiopathische Lungenfibrose. <b>2022</b> , 145-162		
43	Inhaled Treprostinil in PH-ILD - A Success, Finally. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> ,	10.2	1
42	Tartrate-resistant acid phosphatase 5 promotes pulmonary fibrosis by modulating Eatenin signaling.. <i>Nature Communications</i> , <b>2022</b> , 13, 114	17.4	1
41	Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis.. <i>Thorax</i> , <b>2022</b> ,	7.3	3
40	Vardenafil Activity in Lung Fibrosis and In Vitro Synergy with Nintedanib.. <i>Cells</i> , <b>2021</b> , 10,	7.9	0
39	Impact of timing of Nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosis.. <i>Journal of Medical Economics</i> , <b>2022</b> , 1-35	2.4	0
38	[French practical guidelines for the diagnosis and management of IPF´´2021 update, short version].. <i>Revue Des Maladies Respiratoires</i> , <b>2022</b> ,	0	1
37	Advances with pharmacotherapy for the treatment of interstitial lung disease.. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 1-13	4	
36	Herbal Compounds in the Treatment of Pulmonary Silicosis. <i>Physiological Research</i> , S275-S287	2.1	3
35	Herbal Compounds in the Treatment of Pulmonary Silicosis. <i>Physiological Research</i> , S275-S287	2.1	1
34	Sildenafil for idiopathic pulmonary fibrosis: A systematic review and meta-analysis.. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2022</b> , 73-74, 102128	3.5	0
33	Data_Sheet_1.PDF. <b>2020</b> ,		
32	Herbal compounds in the treatment of pulmonary silicosis.. <i>Physiological Research</i> , <b>2021</b> , 70, S275-S287	2.1	1
31	Interstitielle Lungenerkrankungen. <b>2022</b> , 92-102		

30	Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option. <i>Cells</i> , <b>2022</b> , 11, 1626	7.9	1
29	Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis.. <i>New England Journal of Medicine</i> , <b>2022</b> ,	59.2	6
28	Ongoing Clinical Trials in Aging-Related Tissue Fibrosis and New Findings Related to AhR Pathways. <b>2022</b> , 13, 732		0
27	ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly. <i>ERJ Open Research</i> , <b>2022</b> , 8, 00665-2021	3.5	0
26	Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique Actualisation 2021. Version intégrale. <i>Revue Des Maladies Respiratoires</i> , <b>2022</b> ,	0	
25	Clinical Assessment for Pulmonary Hypertension in Interstitial Lung Disease. <i>Internal Medicine Journal</i> ,	1.6	
24	The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD. <i>Advances in Therapy</i> ,	4.1	0
23	Recent advances in the management of pulmonary hypertension with interstitial lung disease. <i>European Respiratory Review</i> , <b>2022</b> , 31, 210220	9.8	2
22	Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative Group 3 pulmonary hypertension. <b>2022</b> , 12,		2
21	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. 2200879		18
20	French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2021 update. Full-length version. <b>2022</b> , 100948		
19	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.		58
18	Pulmonary Hypertension in Interstitial Lung Disease: An area of unmet clinical need. 00272-2022		1
17	Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement. <b>2022</b> , 206, e7-e41		3
16	Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study.		1
15	Antifibrotic in interstitial lung diseases: When, where, and how long?. <b>2022</b> , 39, 491		0
14	Idiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols. <b>2022</b> , 101484		1
13	GLPG1205 for idiopathic pulmonary fibrosis: a Phase 2 randomised placebo-controlled trial. 2201794		0

- 12 PDE5 to keep them alive: The use of phosphodiesterase type-5 inhibitors in severe pulmonary hypertension associated with interstitial lung disease. ○
- 11 Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute® Innovative Drug Development Initiative® Group 3 Pulmonary Hypertension. **2022**, 12, ○
- 10 Pulmonary Hypertension Association® 2022 International Conference Scientific Sessions Overview. ○
- 9 Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data. **2023**, 18, 45 ○
- 8 Idiopathic pulmonary fibrosis: state of the art for 2023. **2023**, 61, 2200957 ○
- 7 Trials and Treatments: An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis. **2023**, 13, 486 ○
- 6 Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis. 14, ○
- 5 Pharmakotherapie der idiopathischen Lungenfibrose (ein Update) und anderer progredienter pulmonaler Fibrosen. **2023**, 77, 94-119 1
- 4 Diagnosis and Pharmacologic Management of Fibrotic Interstitial Lung Disease. **2023**, 13, 599 ○
- 3 Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute® Innovative Drug Development Initiative - Group 3 Pulmonary Hypertension. **2023**, 13, ○
- 2 A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. ○
- 1 The Syndrome of Combined Pulmonary Fibrosis and Emphysema. **2023**, 561-588 ○